Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib

Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. A better understanding of expected outcomes in these patients is necessary to establish a benchmark for evaluating novel agents currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hampel, Paul J., Rabe, Kari G., Call, Timothy G., Ding, Wei, Leis, Jose F., Chanan-Khan, Asher A., Kenderian, Saad S., Muchtar, Eli, Wang, Yucai, Ailawadhi, Sikander, Koehler, Amber B., Parrondo, Ricardo, Schwager, Susan M., Sher, Taimur, Hanson, Curtis A., Shi, Min, Van Dyke, Daniel L., Braggio, Esteban, Slager, Susan L., Kay, Neil E., Parikh, Sameer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437078/
https://www.ncbi.nlm.nih.gov/pubmed/36050317
http://dx.doi.org/10.1038/s41408-022-00721-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437078/
https://www.ncbi.nlm.nih.gov/pubmed/36050317
http://dx.doi.org/10.1038/s41408-022-00721-6

Ejemplares similares